Dendritic-cell-based anticancer vaccination: has it matured?
Fukao
Taro
T
Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. tarofukao@2002.jukuin.keio.ac.jp
D000276:Adjuvants, Immunologic; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D019496:Cancer Vaccines / Q000276:immunology*; D003713:Dendritic Cells / Q000276:immunology*; D005822:Genetic Vectors / Q000276:immunology*; D006801:Humans; D008565:Membrane Proteins / Q000276:immunology; D009369:Neoplasms / Q000628:therapy*; D017430:Prostate-Specific Antigen / Q000276:immunology; D014611:Vaccination
D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D008565:Membrane Proteins; C084881:flt3 ligand protein; D017430:Prostate-Specific Antigen